Literature DB >> 8460634

Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

D F Easton1, D T Bishop, D Ford, G P Crockford.   

Abstract

Breast cancer is known to have an inherited component, consistent in some families with autosomal dominant inheritance; in such families the disease often occurs in association with ovarian cancer. Previous genetic linkage studies have established that in some such families disease occurrence is linked to markers on chromosome 17q. This paper reports the results of a collaborative linkage study involving 214 breast cancer families, including 57 breast-ovarian cancer families; this represents almost all the known families with 17q linkage data. Six markers on 17q, spanning approximately 30 cM, were typed in the families. The aims of the study were to define more precisely the localization of the disease gene, the extent of genetic heterogeneity and the characteristics of linked families and to estimate the penetrance of the 17q gene. Under the assumption of no genetic heterogeneity, the strongest linkage evidence was obtained with D17S588 (maximum LOD score [Zmax] = 21.68 at female recombination fraction [theta f] = .13) and D17S579 (Zmax = 13.02 at theta f = .16). Multipoint linkage analysis allowing for genetic heterogeneity provided evidence that the predisposing gene lies between the markers D17S588 and D17S250, an interval whose genetic length is estimated to be 8.3 cM in males and 18.0 cM in females. This position was supported over other intervals by odds of 66:1. The location of the gene with respect to D17S579 could not be determined unequivocally. Under the genetic model used in the analysis, the best estimate of the proportion of linked breast-ovarian cancer families was 1.0 (lower LOD-1 limit 0.79). In contrast, there was significant evidence of genetic heterogeneity among the families without ovarian cancer, with an estimated 45% being linked. These results suggest that a gene(s) on chromosome 17q accounts for the majority of families in which both early-onset breast cancer and ovarian cancer occur but that other genes predisposing to breast cancer exist. By examining the fit of the linkage data to different penetrance functions, the cumulative risk associated with the 17q gene was estimated to be 59% by age 50 years and 82% by age 70 years. The corresponding estimates for the breast-ovary families were 67% and 76%, and those for the families without ovarian cancer were 49% and 90%; these penetrance functions did not differ significantly from one another.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460634      PMCID: PMC1682082     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  38 in total

1.  Breast cancer in one family group.

Authors:  E J GARDNER; F E STEPHENS
Journal:  Am J Hum Genet       Date:  1950-03       Impact factor: 11.025

2.  Ascertainment and age of onset in pedigree analysis.

Authors:  R C Elston
Journal:  Hum Hered       Date:  1973       Impact factor: 0.444

3.  Six families prone to ovarian cancer.

Authors:  J F Fraumeni; G W Grundy; E T Creagan; R B Everson
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

4.  Linkage analysis of early-onset breast and ovarian cancer families, with markers on the long arm of chromosome 17.

Authors:  N K Spurr; D P Kelsell; D M Black; V A Murday; G Turner; G P Crockford; E Solomon; R A Cartwright; D T Bishop
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

5.  BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis.

Authors:  J S Chamberlain; M Boehnke; T S Frank; S Kiousis; J Xu; S W Guo; E R Hauser; R A Norum; E A Helmbold; D S Markel
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

6.  Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer.

Authors:  A Arason; R B Barkardóttir; V Egilsson
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

7.  THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.

Authors:  A M Bowcock; L A Anderson; L S Friedman; D M Black; S Osborne-Lawrence; S E Rowell; J M Hall; E Solomon; M C King
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

8.  A breast-ovarian cancer susceptibility gene maps to chromosome 17q21.

Authors:  J Feunteun; S A Narod; H T Lynch; P Watson; T Conway; J Lynch; J Parboosingh; P O'Connell; R White; G M Lenoir
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

9.  Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.

Authors:  D E Goldgar; L A Cannon-Albright; A Oliphant; J H Ward; G Linker; J Swensen; T D Tran; P Fields; P Uharriet; M H Skolnick
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

10.  Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21.

Authors:  S A Smith; D F Easton; D Ford; J Peto; K Anderson; D Averill; M Stratton; M Ponder; C Pye; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

View more
  302 in total

1.  The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study.

Authors:  J F Stratton; D Thompson; L Bobrow; N Dalal; M Gore; D T Bishop; I Scott; G Evans; P Daly; D F Easton; B A Ponder
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  BRCA1 can stimulate gene transcription by a unique mechanism.

Authors:  G Nadeau; N Boufaied; A Moisan; K M Lemieux; C Cayanan; A N Monteiro; L Gaudreau
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

Review 3.  Breast cancer in Canada.

Authors: 
Journal:  Can Fam Physician       Date:  1999-08       Impact factor: 3.275

4.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

5.  A model protocol evaluating the introduction of genetic assessment for women with a family history of breast cancer.

Authors:  J Gray; K Brain; P Norman; C Anglim; L France; G Barton; L Branston; E Parsons; A Clarke; J Sampson; E Roberts; R Newcombe; D Cohen; C Rogers; R Mansel; P Harper
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

6.  Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods.

Authors:  P Kraft; D C Thomas
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

7.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

8.  Reading between the lines: direct-to-consumer advertising of genetic testing.

Authors:  S C Hull; K Prasad
Journal:  Hastings Cent Rep       Date:  2001 May-Jun       Impact factor: 2.683

9.  A tale of two genotypes: consistency between two high-throughput genotyping centers.

Authors:  Daniel E Weeks; Yvette P Conley; Robert E Ferrell; Tammy S Mah; Michael B Gorin
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

10.  Toward a model informed consent process for BRCA1 testing: a qualitative assessment of women's attitudes.

Authors:  Barbara A Bernhardt; Gail Geller; Misha Strauss; Kathy J Helzlsouer; Michael Stefanek; Patti M Wilcox; Neil A Holtzman
Journal:  J Genet Couns       Date:  1997-06       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.